上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,15万+投资菁英共同关注小核酸技术正悄悄颠覆心血管代谢领域。诺华Inclisiran作为首个撕开慢病领域PCSK9靶向的siRNA,2021年获批上市,2024年实现7.54亿美元销售,2025Q1的2.57亿美元(同比增长72%),Evaluate Pharma预测其销售峰值有望在2033年达到26亿美元。为什么特指心血管领域?不仅仅是因为...
Source Link上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,15万+投资菁英共同关注小核酸技术正悄悄颠覆心血管代谢领域。诺华Inclisiran作为首个撕开慢病领域PCSK9靶向的siRNA,2021年获批上市,2024年实现7.54亿美元销售,2025Q1的2.57亿美元(同比增长72%),Evaluate Pharma预测其销售峰值有望在2033年达到26亿美元。为什么特指心血管领域?不仅仅是因为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.